CD8A and neoplasm: Conventional dendritic cells type 1 (cDC1s) are capable of cross-presenting tumor antigens to CD8+ cytotoxic T cells and are pivotal in initiating effective anti-tumor responses (Böttcher and Reis e Sousa 2018).